Completed PHASE1 INTERVENTIONAL 3-arm NCT02947854

Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant

An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects

Sponsor: PCI Biotech AS

Conditions Healthy Volunteer

Interventions Fimaporfin (Photosensitizer) HPV E7 (Human Papilloma Virus E7) peptides Hiltonol (Poly-ICLC) KLH (Keyhole Limpet Hemocyanin)

Updated 7 times since 2017 Last updated: Aug 22, 2019 Started: Sep 30, 2016 Primary completion: Mar 26, 2018 Completion: Mar 26, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Volunteer and is currently completed. PCI Biotech AS leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jun 2018 — Sep 2019 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Sep 2017 [monthly]

Recruiting PHASE1

First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PCI Biotech AS

Data source: PCI Biotech AS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leeds, United Kingdom